Cardiol Therapeutics Inc. (CRDL)
Summary
3 Penny Stocks Ready to Break Out in 2025
Known for their uncommonly pronounced risk/reward profile, penny stocks all too often entice investors with their low prices and potential for significant returns, only to fail to live up to those expectations. The world of penny stocks is also characterized by pump-and-dump and other scams, facilitated by the fact that most penny stock companies do not have an extensive history of financial reporting or an established brand name and presence.
Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapy
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced encouraging results from its Phase II MAvERIC-Pilot study, showcasing the sustained efficacy of its anti-inflammatory therapy, CardiolRx, in treating symptomatic recurrent pericarditis. The findings, which were presented at the American Heart Association Scientific Sessions 2024, highlighted marked improvements in pericarditis pain and inflammation, with benefits persisting throughout the 26-week trial.
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
Company advancing late-stage clinical programs with novel therapies that target underserved heart diseases NEW YORK, November 13, 2024 – PRISM MediaWire – PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RS Richard Sproll Tejara Capital Ltd. | 5.13M | $5.89M | $6.18M | $287,724.11 | 4.88% |
 Douglas J. Eaton Eaton Financial Holdings Company LLC | 14,000 | $18,900 | $17,221.4 | -$1,678.6 | -8.88% |
 Shawn Scholz Impact Partnership Wealth, LLC | 10,850 | $10,349 | $13,020 | $2,671 | 25.81% |
 Kevin Bresler TD Waterhouse Canada Inc. | 6,900 | $12,496.33 | $8,142 | -$4,354.33 | -34.84% |
 Scott Noble Boomfish Wealth Group, LLC | 14,423 | $19,471 | $18,545.09 | -$925.91 | -4.76% |
Cardiol Therapeutics Inc. (CRDL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cardiol Therapeutics Inc. ever had a stock split?
Cardiol Therapeutics Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | David G. Elsley CEO | NASDAQ (CM) Exchange | 14161Y200 CUSIP |
| CA Country | 18 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Cardiol Therapeutics Inc. stands as a prominent clinical-stage life sciences organization, primarily engaged in the exploration and development of innovative anti-fibrotic and anti-inflammatory therapies aimed at combating heart diseases. Since its inception in 2017, the company has been dedicated to pioneering solutions for the treatment of complex cardiac conditions. Based in Oakville, Canada, Cardiol Therapeutics is at the forefront of addressing some of the most critical challenges in cardiology today. With a robust focus on research and development, the company aspires to redefine the therapeutic landscape for heart disease patients worldwide.
Products and Services
CardiolRx
CardiolRx is Cardiol Therapeutics' flagship product candidate, currently undergoing an extensive Phase II multi-national, randomized, double-blind, and placebo-controlled study. This rigorous research initiative aims to assess the efficacy and safety of CardiolRx in patients suffering from acute myocarditis, a condition characterized by the inflammation of the heart muscle. Additionally, CardiolRx is being evaluated for its potential in treating recurrent pericarditis, an ailment involving the recurrence of inflammation around the heart's sac. The pivotal trials underway signify the company's commitment to unlocking new therapeutic avenues for heart disease patients.
CRD-38 Injection
In the realm of heart failure, Cardiol Therapeutics is advancing the development of CRD-38 injection, a promising therapeutic designed for subcutaneous administration. Currently in the preclinical phase of development, CRD-38 aims to offer a novel treatment option for heart failure, a prevalent condition that affects millions globally. Through targeting the underlying mechanisms of heart failure, this therapy aspires to improve clinical outcomes and enhance the quality of life for patients. The development of CRD-38 underscores Cardiol's dedication to addressing the unmet medical needs within the sphere of heart disease.
